ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- Potential role of different animal models for the evaluation of bioactive compounds.Annals of medicine and surgery (2012) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that typically requires long-term drug treatment. The emerging role of glucagon-like peptide 1 (GLP-1) and its receptor agonists in gastrointestinal diseases has drawn much attention. A mouse model of acute colitis was conducted using a 7-day protocol of dextran sulfate sodium (DSS, 3% w/v in drinking water) administration. The efficacy of liraglutide (a GLP-1 receptor agonist) in treating DSS-induced colitis and its accompanying Paneth cell metaplasia was examined and correlated to its impact on the levels of colonic autophagy. Liraglutide effectively ameliorated colitis symptoms in mice. Dose-dependent improvements in disease activity index (DAI), colon length, and histopathological scores of inflammation and mucosal damage were evident in the liraglutide-treated groups compared to the DSS group. In addition, liraglutide reduced the expression of lysozyme and suppressed colonic Paneth cell metaplasia induced by DSS. Notably, liraglutide also enhanced levels of colonic autophagy. Direct visualization of autophagosomes and autolysosomes under an electron microscope along with p62 accumulation following co-treatment with chloroquine supports the role of liraglutide as an autophagy enhancer. Liraglutide ameliorated DSS-induced colitis and prevented Paneth cell metaplasia possibly via enhancing colonic autophagy. Our findings strongly signify liraglutide as a therapeutic option for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.